PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
Advances in immunotherapy for triple-negative breast cancer
Y Liu, Y Hu, J Xue, J Li, J Yi, J Bu, Z Zhang, P Qiu… - Molecular cancer, 2023 - Springer
Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
PARP inhibitors: enhancing efficacy through rational combinations
D Bhamidipati, JI Haro-Silerio, TA Yap… - British journal of cancer, 2023 - nature.com
Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …
Development and safety of PI3K inhibitors in cancer
M Yu, J Chen, Z Xu, B Yang, Q He, P Luo, H Yan… - Archives of …, 2023 - Springer
Abstract The phosphatidylinositol 3-kinase (PI3K) signalling pathway regulates cell survival,
proliferation, migration, metabolism and other vital cellular life processes. In addition …
proliferation, migration, metabolism and other vital cellular life processes. In addition …
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
J Ye, J Wu, B Liu - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2023 - Elsevier
Despite some advances in targeted therapeutics of human cancers, curative cancer
treatment still remains a tremendous challenge due to the occurrence of drug resistance. A …
treatment still remains a tremendous challenge due to the occurrence of drug resistance. A …
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Simple Summary Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors
(PARPi) are effective against tumors with mutations in DNA repair genes, most commonly in …
(PARPi) are effective against tumors with mutations in DNA repair genes, most commonly in …
The two sides of chromosomal instability: drivers and brakes in cancer
R Hosea, S Hillary, S Naqvi, S Wu… - Signal Transduction and …, 2024 - nature.com
Chromosomal instability (CIN) is a hallmark of cancer and is associated with tumor cell
malignancy. CIN triggers a chain reaction in cells leading to chromosomal abnormalities …
malignancy. CIN triggers a chain reaction in cells leading to chromosomal abnormalities …
Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies
W Wu, X Xue, Y Chen, N Zheng, J Wang - Pharmacological Research, 2022 - Elsevier
The development of tumor therapeutic resistance is one of the important reasons for the
failure of antitumor therapy. Starting with multiple targets and multiple signaling pathways is …
failure of antitumor therapy. Starting with multiple targets and multiple signaling pathways is …
Phosphoinositide 3-kinase (PI3K) inhibitors and breast cancer: an overview of current achievements
Simple Summary Breast cancer remains the fourth-leading cause of death worldwide, and
therapeutic improvement is warranted. The phosphatidylinositol 3-kinase (PI3K) pathway is …
therapeutic improvement is warranted. The phosphatidylinositol 3-kinase (PI3K) pathway is …